Dyne Therapeutics adds Brian Posner to board of directors

Dyne Therapeutics Inc. (NASDAQ: DYN) announced the appointment of Brian Posner to its board of directors. Posner brings 35 years of executive, investment and board leadership experience to the clinical-stage biotechnology company.

The company focuses on developing treatments for genetically driven neuromuscular diseases and is advancing clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy, with preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.

"Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's board of directors and partner at Atlas Venture.

Posner is founder and president of Point Rider Group (UK) Ltd, an advisory and consulting firm. He previously served as president and CEO of ClearBridge Advisors, a $100 billion+ asset management firm, and as partner and managing director at Warburg Pincus. He also held senior investment roles at Hygrove Partners and Fidelity Investments.

Currently, Posner serves as a director of Arch Capital Group and has previously chaired AQR Funds and Bioverativ, and served as a director of Biogen, Sotheby's and The Mutual Fund Store. He holds degrees from Northwestern University and the University of Chicago Booth School of Business.

"Brian is a highly respected leader whose expertise in investment stewardship, executive leadership and governance will further strengthen our Board," said John Cox, president and CEO of Dyne.

You May Also Be Interested In

• Standard Nuclear names former DOE nuclear policy chief to its board
• Yxt.com Group prices $1.5M registered direct offering at $3 per ADS
• Evolution Metals adds retired Air Force general to its board